Europe acts upon US alert over VRSA (vancomycin-resistant Staphylococcus aureus) testing failures
This article was originally published in Clinica
European regulatory agencies are warning of a risk of failure to detect vancomycin-resistant Staphylococcus aureus (VRSA) using automated antimicrobial susceptibility tests and disc diffusion tests. Their warnings follow a US Centers for Disease Control and Prevention (CDC) alert regarding new cases of confirmed VRSA, which revealed inconsistencies in the results of various testing systems.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.